NGN Capital

Three managing general partners — Kenneth Abramowitz, John Costantino, and Peter Johann — lead the investment committee. Abramowitz brings Wall Street and Carlyle healthcare buyout experience; Costantino contributes tax, operating, and public-company board expertise; Johann supplies global pharma corporate-development knowledge from Boehringer Ingelheim and Roche. Venture partner Kenneth Gorelick and senior advisor William Gedale provide additional clinical and venture-governance input.

The firm leverages a transatlantic network built by Abramowitz during his 23 years as a top-ranked equity analyst and Johann during his tenure at Boehringer Ingelheim and Roche. Gedale’s long-standing ties to research institutions — he arranged funding for Scripps Research Institute and the Neuroscience Institute of La Jolla — provide a university-origination channel that complements the partners’ industry relationships across US and European biotech hubs.

NGN invests across the venture lifecycle, from early-stage and start-up rounds through expansion, late-stage growth, PIPEs, and pre-IPO positions. The firm’s $450 million fund series is structured to support both initial clinical validation and later regulatory- or commercial-stage milestones in therapeutics, medical devices, and diagnostics.

No. NGN maintains offices in Stamford, Connecticut and Heidelberg, Germany, and runs parallel US and German fund vehicles. Peter Johann’s European pharma background and the German office give the firm the ability to diligence and syndicate deals on both sides of the Atlantic.

Kenneth Abramowitz joined NGN from Carlyle, where he was a managing director focused on US healthcare buyouts from 2001 to 2003 and later a senior advisor. NGN was initially conceived as a dedicated healthcare venture vehicle during Abramowitz’s Carlyle tenure, though it now operates as an independent firm with no ongoing Carlyle affiliation.